Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ashwani Bahl"'
Autor:
R. C. Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O’Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-10 (2023)
Abstract Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we rep
Externí odkaz:
https://doaj.org/article/b14be29b81754bafad04d4aa37714251
Autor:
R. C. Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O’Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/4ff05e79a58f49b980db63215fe0a4b3
Autor:
Stevenson Brett W, Stuart Thompson, Ashwani Bahl, Edward K. Ainscow, Damien Crepin, Luke Flatt
Publikováno v:
Cancer Research. 80:5692-5692
CDK12 has emerged as potential target in a range of cancers through its ability to regulate the transcription and mRNA processing of DNA repair genes. Inhibition or knockdown of CDK12 leads to a ‘BRCAness' phenotype caused by low expression of BRCA
Publikováno v:
The Journal of Investigative Dermatology
Mammalian target of rapamycin (mTOR) is essential in controlling several cellular functions. This pathway is dysregulated in keloid disease (KD). KD is a common fibroproliferative dermal lesion with an ill-defined treatment strategy. KD demonstrates